The Effects of Allicor on Patients After Coronary Arteria Revascularization Treatment

Inclusion Criteria: 1. Age \>40 and \<75 years 2. Patients with coronary arteries atherosclerosis for whom coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) is indicated 3. Patients passed a complex of instrumental and laboratory examinations before revascularization, including ECG, echocardiography, visualization of coronary vessels by X-ray contrast angiography, or CT, screening for atherosclerotic lesions of large arteries, including common carotid arteries, abdominal segment of the aorta, arteries of the lower extremities, biochemical analysis of blood included assessment of cholesterol, triglycerides, low density lipoproteins, high density lipoproteins and glucose levels. 4. The possibility of monitoring the patient for 12 months after revascularization, including phone contacts and visits to the clinic after 6 and 12 months. 5. Patient or legal authorized representative capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Exclusion Criteria: 1. Repeated revascularization surgery. 2. Critical and urgent cardiovascular conditions: tissue ischemia stage III-IV, stroke, acute coronary syndrome, myocardial infarction, chronic heart failure III and IV class NYHA (New York Heart Association). 3. Other critical and urgent conditions not associated with cardiovascular diseases, including the need for urgent interventions, chronic renal failure stages IV-V (creatinine clearance \< 30 ml / min according to the Cockcroft-Gault Equation) 4. High degree of disability of the patient (4 or higher points on the modified Rankin scale). 5. History of systemic autoimmune diseases. 6. Significant weight loss (\> 10% of body weight in the previous year) of unknown etiology. 7. Conditions that limit adherence to participation in the study (dementia, neuropsychiatric diseases, drug addiction, alcoholism, etc.). 8. Participation in other clinical studies (or use of investigational substances) within 3 months prior to study entry. 9. Patients with malignant tumors, including the postoperative period with chemotherapy and / or radiation therapy. 10. Carriers of HIV or viral hepatitis 11. Pregnancy or breast feeding 12. Refusal to participate in the study.